Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Change In Receivables : $0.9 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Ironwood Pharmaceuticals Change In Receivables?

Ironwood Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2023 was $-4.6 Mil. It means Ironwood Pharmaceuticals's Accounts Receivable increased by $4.6 Mil from Sep. 2023 to Dec. 2023 .

Ironwood Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $0.9 Mil. It means Ironwood Pharmaceuticals's Accounts Receivable declined by $0.9 Mil from Dec. 2022 to Dec. 2023 .

Ironwood Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2023 was $129.1 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ironwood Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 100.23.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ironwood Pharmaceuticals's liquidation value for the three months ended in Dec. 2023 was $-628.4 Mil.

Ironwood Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Ironwood Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ironwood Pharmaceuticals Change In Receivables Chart

Ironwood Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-68.89

4.09

7.71

7.99

0.92

Ironwood Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															0.94	14.30	-3.24	-5.56	-4.58

Ironwood Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.9 Mil.

Ironwood Pharmaceuticals (NAS:IRWD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ironwood Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	129.122	/	117.553	*	91
=	100.23

2. In Ben Graham's calculation of liquidation value, Ironwood Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Ironwood Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	92.154	-	817.368	+	0.75 * 129.122	+	0.5 * 0
=	-628.4

Ironwood Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (NAS:IRWD) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

I76:Germany I76:Germany

Address

100 Summer Street, Suite 2300, Boston, MA, USA, 02110

Website

https://www.ironwoodpharma.com

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Executives

Marla L Kessler	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Andrew Davis	officer: SVP, Chief Business Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sravan Kumar Emany	officer: SVP, Chief Financial Officer	100 SUMMER ST, SUITE 2300, BOSTON MA 02109
Ronald Silver	officer: Principal Accounting Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Minardo John	officer: Chief Legal Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Thomas A Mccourt	officer: Chief Commercial Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Michael Shetzline	officer: CMO,SVP,Head-Res&Drug	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jason Rickard	officer: SVP, Chief Operating Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark G Currie	officer: Chief Scientific Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Julie Mchugh	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Edward P Owens	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gina Consylman	officer: Chief Accounting Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Kilroy Conor	officer: SVP, GC & Secretary	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110